The prognostic importance of double-expressor subgroup and AID, UNG and mismatch repair protein expressions in diffuse large B-cell lymphomas

Year 2020, , 83 - 89, 31.05.2020

Muhammed Hasan Toper Suheyla Bozkurt Tayfun Elıbol Tulin Tuglular

https://doi.org/10.5472/marumj.741651

Abstract

Objective: The cases of diffuse large B-cell lymphoma, (DLBCL not otherwise specified (NOS)) which immunohistochemically
exhibit MYC and BCL2 expressions are defined as double-expressor lymphomas (DELs). This study aimed to assess the prognostic
impact of DEL and the expressions of other proteins that may have role in tumorogenesis.
Materials and Methods: In this study, 90 tumor samples from patients diagnosed with DLBCL NOS were evaluated retrospectively.
Immunoexpressions of MYC, BCL2, activation-induced cytidine deaminase (AID), uracil-DNA glycosylase (UNG) and DNA
mismatch repair proteins including MLH1, MSH2, MSH6 and PMS2 were analyzed.
Result: Eleven cases (12.2%) which exhibited ≥40% MYC and ≥50% BCL2 immunexpressions were classified as DEL DLBCL. Patients
with MYC positivity displayed lower overall survival rate than MYC negative cases. A trend of lower overall survival was observed in
the double-expressor lymphoma group, however, this was not proven to be statistically significant. Significant relationship between
AID, UNG and p53 immunexpressions with double-expressor lymphoma or overall survival was not detected. The correlation
between immunexpressions of p53 and MYC was observed. The loss of expression of mismatch repair proteins was not observed in
any cases.
Conclusion: In this study, a relationship between low overall survival and MYC expression is detected. However, our result does not
demonstrate that double-expressor lymphoma can be associated with poor outcomes.

Keywords

Diffuse large B-cell lymphoma, Double-expressor lymphoma, MYC, BCL2, AID, Mismatch repair proteins

References

• [1] Schmidt MT, Huang Q, Alkan S. Aggressive B-cell lymphomas: a review and practical approach for the practicing pathologist. Adv Anatomic Pathol 2015;22:168-80. doi: 10.1097/ PAP.000.000.0000000065
• [2] Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 1998;9:717-20. doi: 10.1023/a:100.826.5532487
• [3] Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2017.
• [4] Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121:4021-31; quiz 250. doi: 10.1182/blood-2012-10-460063
• [5] Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3452-9. doi: 10.1200/JCO.2011.41.0985
• [6] Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3460-7. doi: 10.1200/JCO.2011.41.4342
• [7] Perry AM, Alvarado-Bernal Y, Laurini JA, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol 2014;165:382-91. doi: 10.1111/bjh.12763
• [8] Salles G, de Jong D, Xie W, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood 2011;117:7070-8. doi: 10.1182/ blood-2011-04-345256
• [9] Greiner A, Tobollik S, Buettner M, et al. Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma. J Pathol 2005;205:541-7. doi: 10.1002/path.1746
• [10] Ramiro AR, Jankovic M, Callen E, et al. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 2006;440(7080):105-9. doi: 10.1038/nature04495
• [11] Dorsett Y, Robbiani DF, Jankovic M, Reina-San-Martin B, Eisenreich TR, Nussenzweig MC. A role for AID in chromosome translocations between c-myc and the IgH variable region. J Exp Med 2007;204:2225-32. doi: 10.1084/ jem.20070884
• [12] Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet 2008;40:108-12. doi: 10.1038/ng.2007.35
• [13] Liu M, Duke JL, Richter DJ, et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008;451(7180):841-5. doi: 10.1038/nature06547
• [14] Liu M, Schatz DG. Balancing AID and DNA repair during somatic hypermutation. Trends Immunol 2009;30:173-81. doi: 10.1016/j.it.2009.01.007
• [15] Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375-90. doi: 10.1182/ blood-2016-01-643569
• [16] Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82. doi: 10.1182/blood-2003-05-1545
• [17] López-Guillermo A, Colomo L, Jiménez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-804. doi: 10.1200/JCO.2005.07.155
• [18] Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol 2014;89:310-4. doi: 10.1002/ajh.23638
• [19] Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation—a population-based study of 1575 cases. Br J Haematol 2004;124:151-9. doi: 10.1046/j.1365- 2141.2003.04749.x
• [20] Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-804. doi: 10.1200/JCO.2005.07.155
• [21] Hui D, Proctor B, Donaldson J, et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma 2010;51:1658-67. doi: 10.3109/10428.194.2010.504872
• [22] Armitage JO. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997;89:3909-18. doi: 10.1182/blood. V89.11.3909
• [23] Diebold J, Anderson JR, Armitage JO, et al. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma 2002;43:97-104. doi: 10.1080/104.281.90210173
• [24] Carella AM, de Souza CA, Luminari S, et al. Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Molestias Onco-Hematologicas retrospective study. Leuk Lymphoma 2013;54:53-7. doi: 10.3109/10428.194.2012.691482
• [25] Pregno P, Chiappella A, Bellò M, et al. Interim 18-FDGPET/ CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 2012;119:2066-73. doi: 10.1182/ blood-2011-06-359943
• [26] Le Guyader-Peyrou S, Orazio S, Dejardin O, Maynadie M, Troussard X, Monnereau A. Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role? Haematologica 2017;102:584-92. doi: 10.3324/ haematol.2016.152918
• [27] Zhou Z, Sehn LH, Rademaker AW, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 2014;123:837-42. doi: 10.1182/blood-2013-09-524108
• [28] Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857- 61. doi: 10.1182/blood-2006-08-038257
• [29] Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403(6769):503-11. doi: 10.1038/35000501
• [30] Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk 2014;14:460-7 e2. doi: 10.1016/j.clml.2014.05.002
• [31] Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011;117:4836-43. doi: 10.1182/blood-2010-12-322362
• [32] Barrans S, Crouch S, Smith A, Turner K, Owen R, Patmore R, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010;28:3360-5. doi: 10.1200/ JCO.2009.26.3947
• [33] Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010;116:4916-25. doi: 10.1182/blood-2010-03-276766
• [34] Hong J, Park S, Park J, et al. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy. Annals Hematol 2012;91:1897-906. doi: 10.1007/s00277.012.1533-z
• [35] Seki R, Ohshima K, Fujisaki T, et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B‐cell lymphoma in the rituximab era. Cancer Sci 2009;100:1842-7. doi: 10.1111/j.1349-7006.2009.01268.x
• [36] Stavnezer J. Complex regulation and function of activationinduced cytidine deaminase. Trends Immunol 2011;32:194- 201. doi: 10.1016/j.it.2011.03.003
• [37] Willenbrock K, Renne C, Rottenkolber M, et al. The expression of activation induced cytidine deaminase in follicular lymphoma is independent of prognosis and stage. Histopathology 2009;54:509-12. doi: 10.1111/j.1365- 2559.2009.03241.x
• [38] Shi Y, Zhao X, Durkin L, Rogers HJ, Hsi ED. Aberrant activation-induced cytidine deaminase expression in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. Hum Pathol 2016;52:173-8. doi: 10.1016/j. humpath.2016.01.008
• [39] Lossos IS, Levy R, Alizadeh AA. AID is expressed in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas and is not correlated with intraclonal heterogeneity. Leukemia 2004;18:1775-9. doi: 10.1038/ sj.leu.2403488
• [40] Greeve J, Philipsen A, Krause K, et al. Expression of activation-induced cytidine deaminase in human B-cell non- Hodgkin lymphomas. Blood 2003;101:3574-80. doi: 10.1182/ blood-2002-08-2424
• [41] Engels K, Jungnickel B, Tobollik S, Hansmann M L, Kriener S, Willenbrock K. Expression of activation-induced cytidine deaminase in malignant lymphomas infiltrating the bone marrow. Appl Immunohisto M M 2008;16:521-9. doi: 10.1097/ PAI.0b013e3181758ce5
• [42] Gu X, Booth CJ, Liu Z, Strout MP. AID-associated DNA repair pathways regulate malignant transformation in a murine model of BCL6-driven diffuse large B-cell lymphoma. Blood 2016;127:102-12. doi: 10.1182/blood-2015-02-628164
• [43] Rossi D, Rasi S, Di Rocco A, et al. The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. Blood 2011;117:2405-13. doi: 10.1182/blood-2010-07-296244
• [44] Couronne L, Ruminy P, Waultier-Rascalou A, et al. Mutation mismatch repair gene deletions in diffuse large B-cell lymphoma. Leuk Lymphoma 2013;54:1079-86. doi: 10.3109/10428.194.2012.739687
• [45] Lu TX, Young KH, Xu W, Li JY. TP53 dysfunction in diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2016;97:47- 55. doi: 10.1016/j.critrevonc.2015.08.006
• [46] Wang XJ, Medeiros LJ, Bueso-Ramos CE, et al. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Mod Pathol 2017;30:194-203. doi: 10.1038/ modpathol.2016.178
• [47] Li S, Weiss VL, Wang XJ, et al. High-grade B-cell lymphoma with MYC rearrangement and without BCL2 and BCL6 rearrangements is associated with high P53 expression and a poor prognosis. Am J Surg Pathol 2016;40:253-61. doi: 10.1097/PAS.000.000.0000000542
• [48] Tessoulin B, Eveillard M, Lok A, et al. p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Blood Rev 2017;31:251-9. doi: 10.1016/j.blre.2017.03.001
• [49] Fiskvik I, Beiske K, Delabie J, et al. Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma. Leuk Lymphoma 2015;56:1742-9. doi: 10.3109/10428.194.2014.970550
• [50] Schiefer AI, Kornauth C, Simonitsch-Klupp I, et al. Impact of single or combined genomic alterations of TP53, MYC, and BCL2 on survival of patients with diffuse large B-cell lymphomas: A retrospective cohort study. Medicine (Baltimore) 2015;94:e2388. doi: 10.1097/MD.000.000.0000002388